AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05873803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR1802 injection
Description: 150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
Study NCT05873803 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
Study NCT05306444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-418
Description: Intravenous (IV) administration
Study NCT06004063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN)
Description: Given by Nasogastric Tube
Study NCT06004063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care parenteral nutrition (PN)
Description: Given by PO or Given by IV (vein)
Study NCT06004063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care parenteral nutrition (PN)
Description: Given by PO or Given by IV (vein)
Study NCT05429021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-BCP-01
Description: Single dose of IMM-BCP-01
Study NCT05429021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of IMM-BCP-01
Study NCT06085729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: Given by Injection
Study NCT06085729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given by IV (vein)
Study NCT05033145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZVUDINE
Description: AZVUDINE 5 tablets QD + standard treatment, for up to 14 days
Study NCT05033145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZVUDINE placebo
Description: 5 tablets QD + standard treatment, for up to 14 days
Study NCT04685681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hiking challenge
Description: The main intervention of interest is the provision of free access to a local hiking challenge (which is provided following baseline assessments in the experimental group and after the conclusion of the study in the control group; $20 value). If participants choose to sign up for the free hiking challenge, they receive a list of local hikes/nature walks, accompanying maps, scavenger-hunt-like activities (finding a certain landmark on each hike), and the opportunity to earn prizes and engage with other hikers on social media.
Study NCT06085729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV (vein)
Study NCT06085092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open weighing
Description: The open-weighing intervention aims to challenge beliefs about weight gain. The study coordinator (SC) will explain open weighing, discuss any concerns you have about your weight, and construct a weight graph with the number of weeks on the x-axis and weight in pounds on the y-axis. The SC will help identify beliefs about gaining weight, which will be written on a Feared Outcomes Form. The SC will ask you to predict your weight, mark the weight prediction on the graph, weigh you on a standing scale, record your weight, and discuss your responses to seeing your weight, including any reasons for a difference between your predicted and actual weight. Each week, the SC will graph your actual and predicted weights over time and discuss anything that you are learning from this process. The SC will ask you to complete the Feared Outcomes Form once per day over the next week, review it each week, and talk to you about what you are learning from this process.
Study NCT06085092 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Blind weighing
Description: The blind weighing intervention aims to help you see self-weighing as an eating disorder symptom that you should stop, and that weight is not important to your identity or self-esteem. To do this, the study coordinator will explain why blind weighing might be helpful. You will then be asked to step backwards on a standing scale. The study coordinator will record your weight but will not share your weight information with you. The study coordinator will discourage you from thinking or talking about your weight.
Study NCT06094933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Anger Reduction Intervention (MARI)
Description: This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will download the MARI app and be instructed to complete at least 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
Study NCT06094933 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Condition (HED)
Description: This is a mobile application that delivers videos with psychoeducation about healthy habits and selfcare for general wellness. Participants will download the HED app and be instructed to use it at least 5 times a week for a period of 4 weeks.
Study NCT06570785 — intervention group
Intervention type: DEVICE
Intervention: Intra-Operative Positioning System (IOPS)
Description: This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the use of contrast dye and radiation exposure for patients and healthcare professionals alike. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The console is operated by a technician under a physician's instruction. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed.
Study NCT06570785 — intervention group
Intervention type: DEVICE
Intervention: Conventional group
Description: This group will be treated using standardised materials (wires, catheters) during EVAR.
Study NCT04685681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity list
Description: The control group will receive a list of CDC-recommended activities following the baseline survey and will receive the hiking challenge as a delayed intervention following post-test.
Study NCT04891692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimaWell 120MTRS system
Description: Medium-frequency electrotherapy device that delivers current via up to 12 channels. The device also provides heat therapy up to 40°C.
Study NCT05898932 — intervention group
Intervention type: OTHER
Intervention: Medical Management
Description: Participants will be managing condition with medication
Study NCT05898932 — intervention group
Intervention type: OTHER
Intervention: Surgical Management
Description: Participants will be managing condition with a surgery
Study NCT06533332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERX-315
Description: Drug administered intravenously twice a week at increasing dose levels, with starting dose of 0.4mg/kg.
Study NCT05349136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronous telerehabilitation group
Description: This group will receive Action Observation Treatment with a synchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under the supervision of a physiotherapist via videoconferencing.
Study NCT05349136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asynchronous telerehabilitation group
Description: This group will receive Action Observation Treatment with an asynchronous telerehabilitation method. Children in this group will be applied Action Observation Treatment 5 days a week for 3 weeks, for a total of 15 sessions under parental supervision.
Study NCT05252988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib orally once daily for 13 cycles, unless patient discontinues earlier.
Study NCT05883267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: PICO model neo 2 VR glasses
Study NCT05883267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vocal-guided affective imagery
Description: Audio via telephone
Study NCT05500547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: US Public Health Service USPSH criteria for assessment of success of resin composite restorations
Description: US Public Health Service USPSH criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months.
Study NCT05500547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US Public Health Service USPSH criteria for assessment of success of resin composite restorations
Description: US Public Health Service USPSH criteria for color match, marginal adaptation, surface texture, retention, recurrent caries and others after 1, 3, 6 and 9 months.
Study NCT06527547 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Transcutaneous auricular vagus nerve stimulation(taVNS) , as an emerging neuromodulation therapy, integrates China's traditional meridian and acupoint theory with transcutaneous electrical nerve stimulation technology, representing a non-invasive, simple alternative therapy. Electrical stimulation of auricular points (areas on the ear following the vagus nerve pathway) stimulates the parasympathetic system, leading to slow-wave sleep through activation of the reticular formation. Vagus nerve stimulation can also regulate sleep by altering concentrations of neurotransmitters such as gamma-aminobutyric acid (GABA), norepinephrine, and serotonin, making it a safe and effective method for treating primary sleep disorders. In rheumatoid arthritis (RA), studies have shown that vagus nerve stimulation can reduce disease activity and serum levels of inflammatory cytokines.
Study NCT06527547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Transcutaneous auricular vagus nerve stimulation(taVNS) , as an emerging neuromodulation therapy, integrates China's traditional meridian and acupoint theory with transcutaneous electrical nerve stimulation technology, representing a non-invasive, simple alternative therapy. Electrical stimulation of auricular points (areas on the ear following the vagus nerve pathway) stimulates the parasympathetic system, leading to slow-wave sleep through activation of the reticular formation. Vagus nerve stimulation can also regulate sleep by altering concentrations of neurotransmitters such as gamma-aminobutyric acid (GABA), norepinephrine, and serotonin, making it a safe and effective method for treating primary sleep disorders. In rheumatoid arthritis (RA), studies have shown that vagus nerve stimulation can reduce disease activity and serum levels of inflammatory cytokines.
Study NCT05294367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Chloride-based Lotion
Description: Given topically
Study NCT05294367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05294367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Diet Therapy
Description: Consume magnesium rich foods
Study NCT05263713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture Closure of Linear Wounds
Description: Half of the wound is repaired with running subcuticular sutures and the other half is repaired with running horizontal mattress sutures.
Study NCT05796167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks
Study NCT06336161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: to compare between Ultrasound-Guided ESPB and Ultrasound-Guided CEI for postoperative pain relief in patients who underwent lumbosacral surgeries.
Study NCT05681169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School-based HPV-counselling and HPV-vaccination.
Description: 1. Scholl-based parental HPV-counselling~2. Scholl-based pupil HPV-counselling~3. Scholl-based HPVV
Study NCT04765059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Description: Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin
Study NCT04765059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Description: Randomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin
Study NCT06488807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory Enrichment
Description: Each participant will be equipped with an electrical odor dispenser which allowed to distribute 8 odors (grapefruit, lavender, lemon, peppermint, menthol, tangerine, green tea, and bergamot). The choice of odors was guided by (1) pleasantness of the odors, (2) presence of slight trigeminal activation in some of the odors, e.g., peppermint, (3) evaporation characteristics, so that the odors would last for the duration of the experiment, (4) technical issues mostly in terms of compatibility with the odor cartridge, (5) availability, and (6) inspiration from the previous studies.
Study NCT06488807 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Water will be used in the dispenser.
Study NCT05252988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide orally.
Study NCT05252988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam capsules orally, 2 times a day for the first month (28 days).
Study NCT06475235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized immunoglobin G4 monoclonal antibody, 4 mL vials, via intravenous infusion (into the vein) per protocol.
Study NCT06475235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Anti-metabolite, 50 mL vials, via intravenous infusion per protocol.
Study NCT06475235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsules, taken orally per protocol.
Study NCT06475235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Anti-CD20 antibody, 10 or 50 mL single-use vials, via intravenous infusion per standard of care.
Study NCT05874219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local antibiotic spray Neomycin sulphate 165,000 IU + Bacitracin zinc 12,500 IU
Description: The intervention Sprayed 1 to 3 times /day
Study NCT04313712 — intervention group
Intervention type: DRUG
Intervention: ibogaine with magnesium treatment
Description: Participants will receive magnesium sulfate intravenously and ibogaine orally.
Study NCT05874219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin 2% ointment
Description: 10 mm of mupirocin ointment squeezed directly on to their exit sites from a 15 g tube with an outlet diameter of 5 mm
Study NCT04792151 — intervention group
Intervention type: BEHAVIORAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents
Description: The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C and UP-A) are transdiagnostic, behavioral interventions for youth with emotional disorders, including anxiety, depression, obsessive-compulsive disorders, and irritability.
Study NCT06476184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy
Study NCT06476184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy
Study NCT06476184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy
Study NCT06291077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Changing of anticalcineurins by Belatacept
Study NCT06291077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anticalcineurins
Description: Keeping of anticalcineurins
Study NCT06476184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy
Study NCT04695730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active physical therapy (including both pain education and home exercises)
Description: One session (60 minutes). In this session, a physical therapist will explain and demonstrate the exercises to perform individually at home. Exercises will be performed daily. In addition, an education session will be provided, concerning pain mechanisms and management. To support patients during the treatment, a booklet will be created.~One booster session (30minutes) will be planned after 4 weeks. Patients will follow the active treatment for 8 weeks.
Study NCT04695730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active physical therapy plus manual therapy
Description: Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist.
Study NCT04954469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoVAC-1
Description: Peptide vaccination should be started as soon as possible after the screening visit.
Study NCT01924897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Study NCT06332053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5007
Description: SY-5007 80 mg, Tablets, 2 discrete single doses at Day 1 and Day 11
Study NCT06332053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg, Capsules, Day 8-Day 18
Study NCT06332053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5007
Description: SY-5007 160 mg, Tablets, 2 discrete single doses at Day 1 and Day 16
Study NCT06332053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 600 mg, Capsules, Day 8-Day 21
Study NCT05705050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline group
Description: Patients will receive 4 mg/kg aminophylline diluted in 100 ml normal saline over 20 minutes after induction of anesthesia and positioning of patients in lithotomy position.
Study NCT05705050 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Patients will receive 100 ml normal saline over 20 minutes after induction and lithotomy positioning.
Study NCT05211505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WO 2707
Description: Intravaginal application once daily for 1 week, then twice per week until visit 3 (day 38).
Study NCT05161117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality simulation app for caregiver education
Description: Using a virtual reality headset/goggles, caregivers will engage with an interactive app experience to identify and mediate fall risk hazards in the inpatient care environment. The app will present a hospital bedroom and bathroom laden with fall risks. As the caregiver progresses through the experience, the caregiver will ambulate (virtually) through the environment with the goal of identifying fall risks inherent within that inpatient setting. Fall risks will be targeted and identified using the app sighting function and after focusing on the fall risk for the allotted marking time, will self-resolve.
Study NCT05161117 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: online fall prevention education module
Description: Participants in both intervention and control groups will complete a 20 minute online module: Management of the Patient at Risk for Falls, through the MyLearning education platform. Most caregivers would have taken this module during competencies or orientation, but at various times. It will be taken by all participants in this study to serve as a baseline understanding of identifying and caring for patients at risk for falls. Participants will be enrolled in the module by a member of the research team, and learner transcripts will available through MyLearning education to confirm completion.